Tyra Biosciences, Inc. (TYRA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$24.61

From 52W high−35.04%

Volume2.04M

Market cap$1.77B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$24.61

From 52W high

−35.04%

Volume

2.04M

Market cap

$1.77B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−9.6x

P/E (TTM)

—

RSI (14)

48.4

MomentumView details →

1D Return

+5.32%

YTD Return

−4.09%

SummaryUpdated Jun 1, 2026

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Carlsbad, California. The company went public in September 2021 and focuses on developing innovative cancer therapies designed to overcome tumor resistance mechanisms that limit the effectiveness of existing treatments. Tyra specializes in precision oncology, utilizing its proprietary SNAP platform to design targeted therapies against specific genetic mutations that drive cancer growth and resistance.

Ask drillr about Tyra Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−9.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

5.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−42.01%

ROA (TTM)

−38.75%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−34.83%

FCF YoY

−26.72%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−33.11%

EBITDA YoY

−29.80%

MomentumView details →

1D Return

+5.32%

YTD Return

−4.09%

1Y Return

+101.72%

RSI (14)

48.4

vs 50D SMA

−8.89%

vs 200D SMA

−17.10%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

14.91x

Quick Ratio

14.91x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.69

EPS Surprise

−6.17%

Beats (12Q)

7/12

Next Q EPS Est

−$0.67

Avg Surprise (4Q)

−0.38%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−148.56M

Op. CF (TTM)

−109.65M

Next earningsNov 4, 2026 →

Latest newsMore news →

Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 per share and pre-funded warrants for 9,078,529 shares at $22.029 each, raising about $400 million.6d ago

Tyra Biosciences announced initial results from its Phase 2 SURF302 trial of oral dabogratinib, establishing clinical proof of concept and selecting a 60 mg once-daily dose for planned registrational studies.11d ago

Similar companies

Vir Biotechnology, Inc.VIR Septerna, Inc.SEPN Stoke Therapeutics, Inc.STOK Xencor, Inc.XNCR Guangzhou Innogen Pharmaceutl Grp Co Ltd02591.HK Intellia Therapeutics, Inc.NTLA Find similar companies →

Latest newsMore news →

Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 per share and pre-funded warrants for 9,078,529 shares at $22.029 each, raising about $400 million.6d ago Tyra Biosciences announced initial results from its Phase 2 SURF302 trial of oral dabogratinib, establishing clinical proof of concept and selecting a 60 mg once-daily dose for planned registrational studies.11d ago